Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety of GSK2398852 When Co-administered With GSK2315698 in Patients With Systemic Amyloidosis

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject has been medically diagnosed with systemic amyloidosis and falls into one of the patient groups (small to moderate amyloid load involving the spleen for Part A; moderate to large amyloid load involving the spleen (to a moderate/large extent) for Part A (following agreement from external safety committee); moderate to large amyloid load involving the spleen and liver (spleen involved to a moderate/large extent) for Part A extension (if required); and moderate to large amyloid load involving the spleen (and liver in subset of subjects only) for Part B).~* Alanine aminotransferase (ALT) \<3x upper limit of normal (ULN) and bilirubin \<1.5x ULN (isolated bilirubin \>1.5x ULN is acceptable if bilirubin is fractionated and direct bilirubin \<35%).~* Male or female between 18 and 70 years of age inclusive, at the time of signing the informed consent.~* Subject is ambulant and capable of attending for the study visit schedule.~* Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.~* A female subject is eligible to participate if she is of non-childbearing potential; or females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use one of the approved contraception methods.~* Male subjects with female partners of child-bearing potential must agree to use one of the approved contraception methods.~* Smokers (\<10 /day) are permitted but must be willing to abstain for the duration of residential study sessions~Exclusion Criteria:~* A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months of screening~* The subject has participated in a clinical trial and has received an investigational therapeutic product (unlicensed) within the following time period prior to the first dosing day in the current study: 3 months, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer). This timeframe will not apply to short term administration of GSK2315698 in study CPH114527.~* Pregnant females as determined by positive serum or urine human chorionic gonadotropin (hCG) test at screening or prior to dosing.~* Lactating females.~* Estimated glomerular filtration rate (GFR)\<30 milliliter (mL)/minute (min) \[\<60 mL/min for the first 4 subjects to be enrolled\]~* Evidence of an active urinary sediment on microscopy as evidenced by the presence of red cell casts~* Decompensated cardiac failure or a recent history of syncope associated with cardiac disease.~* In a subject in whom there is a clinical suspicion of cardiac amyloid, an echocardiogram is consistent with significant cardiac amyloid, whether symptomatic or not.~* Clinically significant anaemia- hemoglobin (Hb) \<9 gram (g)/deciliter (dL).~* Use of prohibited medications.~* Poor or unsuitable venous access.~* Subjects with a QT interval corrected using Fridericia's formulas (QTcF) of \>480 ms or other electrocardiogram (ECG) abnormalities which, in the opinion of the investigator are clinically significant and may increase safety risk.~* Uncontrolled hypertension with systolic blood pressure (BP) \>170 mmHg and /or diastolic \>100 mmHg~* Presence of any co-morbid condition (e.g. severe or unstable coronary artery disease; moderate-severe chronic obstructive pulmonary disease) which in the opinion of the investigator would increase the potential risk to the subject.~* Subjects with active vasculitis~* Exclusions from Equilibrium contrast Magnetic Resonance Imaging (EqMRI) scanning \[Contraindications to Magnetic Resonance Imaging (MRI) scanning including, but not limited to: Intracranial aneurism clips (except Sugita); History of intra-orbital metal fragments that have not been removed by an MD (as confirmed by orbital X-Ray); Pacemakers and non-MR compatible heart valves; Inner ear implants; History of claustrophobia; estimated GFR \<30 mL/min (gadolinium exclusion)\]~* Subjects with dementia or a diagnosis of cerebral amyloid angiopathy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Part A Arm (Type: EXPERIMENTAL): Two subjects in Part A will receive starting dose level of GSK2398852 as 5 milligram (mg) \[approximately equivalent to 0.1 mg/kilogram (kg)\]. The next escalation dose levels in two subjects each are proposed as 1 mg/kg, 3 mg/kg, 10 mg/kg and 30 mg/kg. GSK2315698 will be administered at variable dosed until the concentration of the SAP mAb has fallen below 100 ng/mL.
- Part B Arm (Type: EXPERIMENTAL): The precise selection of numbers of subjects and dose levels in Part B will be informed by the results from Part A.

Based on this trial design, predict the completion outcome and termination type (if applicable).